Down Syndrome Pipeline Review, H2 2020: Therapeutic Analysis of 14 Companies & 3 Drug Profiles – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Down Syndrome – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Down Syndrome – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Down Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Down Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 4, 7, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Down Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Down Syndrome (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Down Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

(Read more…)

• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Down Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Down Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Down Syndrome (Genetic Disorders)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Down Syndrome (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Down Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

1. Introduction
2. Report Coverage
3. Down Syndrome – Overview
4. Down Syndrome – Therapeutics Development
5. Pipeline Overview
6. Pipeline by Companies
7. Pipeline by Universities/Institutes
8. Products under Development by Companies
9. Products under Development by Universities/Institutes
10. Down Syndrome – Therapeutics Assessment
11. Assessment by Target
12. Assessment by Mechanism of Action
13. Assessment by Route of Administration
14. Assessment by Molecule Type

Down Syndrome – Companies Involved in Therapeutics Development

• AC Immune SA
• Aelis Farma SAS
• Alzheon Inc
• Annovis Bio Inc
• Avanti Biosciences Inc
• Balance Therapeutics Inc
• Eisai Co Ltd
• Elixirgen Therapeutics LLC
• F. Hoffmann-La Roche Ltd
• KinoPharma Inc
• ManRos Therapeutics
• NeuroCircuit Therapeutics Inc
• NeuroNascent Inc
• San Biotechnology Co Ltd

Down Syndrome – Drug Profiles

• ABI-02 – Drug Profile
• ACI-24 – Drug Profile
• AEF-0217 – Drug Profile

Featured News & Press Releases

• Jul 11, 2019: AC Immune hosts KOL event and reports initial interim clinical data for ACI-24 vaccine to treat Alzheimer’s Disease-like symptoms in subjects with Down Syndrome
• Aug 20, 2018: AC Immune announces important clinical milestones for ACI-24 vaccine in alzheimers disease and down syndrome
• Sep 12, 2017: AC Immune Completes Recruitment For Low-Dose Cohort In World’s First Clinical Trial For Anti-Abeta Vaccine Targeting Alzheimer’s Disease-Like Characteristics In Individuals With Down Syndrome
• Jul 11, 2017: QR Pharma Presents New Data on Posiphen in Down Syndrome at the Alzheimer’s Disease International Conference
• Apr 05, 2016: AC Immune Announces Publication of Ground-breaking Scientific Publication on anti-Abeta Vaccine in Preclinical Model of Down Syndrome
• Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics
• Feb 27, 2013: Roche Research Sheds Light On Improving Neurological Deficits In Mouse Model Of Down Syndrome

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/okede3

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900